Immunoscintigraphy of colon carcinoma

Area of Science:

• Oncology
• Immunology
• Nuclear Medicine

Background:

• Monoclonal antibodies are crucial tools in cancer research and therapy.
• Radioimmunodetection utilizes labeled antibodies for imaging cancer sites.
• Specific antibodies targeting gastrointestinal cancers offer diagnostic potential.

Purpose of the Study:

• To evaluate the efficacy of Iodine-131 labeled monoclonal antibodies for scintigraphic detection of human gastrointestinal cancers.
• To assess the diagnostic accuracy of antibodies 17-1A and 19-9 in identifying colorectal cancer sites.

Main Methods:

• Administered Iodine-131 labeled monoclonal antibodies (17-1A, 19-9, or fragments) to 90 cancer patients.
• Performed scintigraphy for cancer site detection.
• Correlated immunoscintigraphy results with immunoperoxidase studies on resected tissues in a subset of patients.

Main Results:

• Antibody 17-1A accumulated significantly in 59% of colorectal cancer sites, sparing other cancer types.
• Antibody 19-9 showed significant accumulation in 66% of colorectal cancer sites.
• Combined antibody use (17-1A + 19-9 or anti-CEA + 19-9) demonstrated high positivity rates (10/13 sites).

Conclusions:

• Iodine-131 labeled monoclonal antibodies 17-1A and 19-9 are effective for scintigraphic detection of colorectal cancer.
• Immunoscintigraphy shows promise as a diagnostic tool for gastrointestinal malignancies.
• Further research may enhance the utility of these antibodies in clinical oncology.